ICOS and cancer: Treatment with anti-ICOS agonistic mAb or anti-ICOS antagonistic mAb to treat cancers by enhancing the function of effector T cells and/or depleting ICOShi Tregs alone or in combination with other monoclonal antibodies such as nivolumab and ipilimumab has achieved great success and has been a hot spot in cancer immunotherapy (145).